Page 5 - John Bluth News Today

BioCryst Appoints Machelle Sanders to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 --... | November 29, 2021

BCRX earnings call for the period ending September 30, 2021.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang...

BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer - read this article along with other careers information, tips and advice on BioSpace

BioCryst Pharmaceuticals (BCRX) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. BioCryst Pharmaceuticals (NASDAQ: BCRX) Ladies and gentlemen, thank you for standing by, and welcome to the BioCrysts first-quarter 2021 earnings call. [Operator instructions] I would now like to hand the conference over to your speaker today, Mr. John Bluth of BioCryst. John, the floor is yours. John Bluth -- Senior Vice Presid...

ORLADEYO ™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.  One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. The full European Summary of Product Characteristics (SMPC) for ORLADEYO will be available from the European Medicines Association website at About BioCryst Pharmaceuticals BioCryst Pharmaceuticals ...

ORLADEYO ™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older.  One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. The full European Summary of Product Characteristics (SMPC) for ORLADEYO will be available from the European Medicines Association website at About BioCryst Pharmaceuticals BioCryst Pharmaceuticals ...